{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:45:50Z","timestamp":1776368750923,"version":"3.51.2"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bulcan.2024.10.013","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:30:32Z","timestamp":1734611432000},"page":"208-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaccination des enfants et adolescents trait\u00e9s pour une leuc\u00e9mie aigu\u00eb, hors allogreff\u00e9s\u00a0: recommandations du comit\u00e9 leuc\u00e9mies de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers et les leuc\u00e9mies de l\u2019enfant et de l\u2019adolescent (SFCE)"],"prefix":"10.1016","volume":"112","author":[{"given":"Aphaia","family":"Roussel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"L\u00e9glise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Rialland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myl\u00e8ne","family":"Duplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Falaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude Marie","family":"Cardine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lia","family":"Alimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Rabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9o","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliz\u00e9e","family":"Corbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrystelle","family":"Dupraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Lervat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-5180","authenticated-orcid":false,"given":"Fanny","family":"Alby-Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1634\/stemcells.18-1-10","article-title":"T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review","volume":"18","author":"Mackall","year":"2000","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0385","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00043426-199809000-00008","article-title":"Immune recovery in children with malignancy after cessation of chemotherapy","volume":"20","author":"Mustafa","year":"1998","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.10.013_bib0390","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/pbc.21864","article-title":"Immunization after the elective end of antineoplastic chemotherapy in children","volume":"52","author":"Fioredda","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.bulcan.2024.10.013_bib0395","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/INF.0b013e318267f7d9","article-title":"Clinical and demographic characteristics of seasonal influenza in pediatric patients with cancer","volume":"31","author":"Carr","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0400","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/pbc.21472","article-title":"Influenza-associated morbidity in children with cancer","volume":"50","author":"Tasian","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0405","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/tid.12013","article-title":"Epidemiology and clinical characteristics of pandemic (H1N1) 2009\u00a0influenza infection in pediatric hemato-oncology and hematopoietic stem cell transplantation patients","volume":"14","author":"Babor","year":"2012","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"10.1016\/j.bulcan.2024.10.013_bib0410","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0415","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/1097-0142(19920315)69:6<1481::AID-CNCR2820690628>3.0.CO;2-L","article-title":"Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia","volume":"69","author":"Alanko","year":"1992","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/08880019409141671","article-title":"Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia","volume":"11","author":"Alanko","year":"1994","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.10.013_bib0425","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.leu.2404326","article-title":"Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review","volume":"20","author":"van Tilburg","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0430","unstructured":"Haut Conseil de Sant\u00e9 Publique HCSP. Vaccination des personnes immunod\u00e9prim\u00e9es ou aspl\u00e9niques Recommandations [Internet]. 2014. Disponible sur\u00a0: https:\/\/www.hcsp.fr\/Explore.cgi\/Accueil."},{"issue":"11S","key":"10.1016\/j.bulcan.2024.10.013_bib0435","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0440","unstructured":"Calendrier des vaccinations et recommandations vaccinales 2024, BEH, minist\u00e8re du Travail, de la Sant\u00e9 et des Solidarit\u00e9s [Internet]. 2024. Disponible sur\u00a0: https:\/\/sante.gouv.fr\/IMG\/pdf\/calendrier_vaccinal_avr2024.pdf."},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0445","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/pbc.22135","article-title":"Humoral immunity to diphtheria, tetanus, measles, and hemophilus influenzae type b in children with acute lymphoblastic leukemia and response to re-vaccination","volume":"53","author":"Zengin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0450","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pbc.20255","article-title":"Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group","volume":"44","author":"Ek","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0455","doi-asserted-by":"crossref","first-page":"e30321","DOI":"10.1002\/pbc.30321","article-title":"Revaccination of children with acute lymphoblastic leukemia following completion of chemotherapy","volume":"70","author":"Anafy","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0460","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/511636","article-title":"Revaccination of children after completion of standard chemotherapy for acute leukemia","volume":"44","author":"Patel","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0465","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1093\/cid\/ciac570","article-title":"Longitudinal immune response to 3\u00a0doses of messenger RNA vaccine against Coronavirus disease 2019 (COVID-19) in pediatric patients receiving chemotherapy for cancer","volume":"76","author":"Lehrnbecher","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0470","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/cncr.20384","article-title":"Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy","volume":"101","author":"Zignol","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0475","unstructured":"OMS juin 2023, s\u00e9curit\u00e9 transfusionnelle et approvisionnement en sang. Disponible sur\u00a0: https:\/\/www.who.int\/fr\/news-room\/fact-sheets\/detail\/blood-safety-and-availability."},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0480","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12887-017-0924-7","article-title":"Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012\u00a0to 2015\u00a0in an urban of South Korea","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Pediatr"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0485","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/08880011003602141","article-title":"Humoral immunity against hepatitis B, tetanus, and diphtheria following chemotherapy for hematologic malignancies: a report and review of literature","volume":"27","author":"Alavi","year":"2010","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2024.10.013_bib0490","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/pbc.26110","article-title":"Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer","volume":"63","author":"Choi","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2024.10.013_bib0495","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1002\/cnr2.1907","article-title":"Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation","volume":"6","author":"Pearson","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0500","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jpeds.2004.12.043","article-title":"Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens","volume":"146","author":"Brodtman","year":"2005","journal-title":"J Pediatr"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0505","article-title":"HBV seroprotection and anamnestic response to booster vaccination in pediatric cancer survivors","volume":"8","author":"Suwanpakdee","year":"2021","journal-title":"Glob Pediatr Health"},{"issue":"4","key":"10.1016\/j.bulcan.2024.10.013_bib0510","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0145-2126(98)00189-1","article-title":"vaccination in children with acute lymphoblastic leukemia: results of an intensified immunization schedule","volume":"23","author":"Somjee","year":"1999","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.bulcan.2024.10.013_bib0515","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0145-2126(00)00101-6","article-title":"Two booster dose hepatitis B virus vaccination in patients with leukemia","volume":"25","author":"Yetgin","year":"2001","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.bulcan.2024.10.013_bib0520","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.leukres.2006.06.024","article-title":"Unexpected protection from infection by two booster hepatitis B virus vaccination in children with acute lymphoblastic leukemia","volume":"31","author":"Yetgin","year":"2007","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.bulcan.2024.10.013_bib0525","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/00006454-199511000-00002","article-title":"Impaired response to hepatitis B vaccine in children receiving anticancer chemotherapy","volume":"14","author":"Hovi","year":"1995","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0530","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00431-017-2970-4","article-title":"Assessment of hepatitis B virus antibody titers in childhood cancer survivors","volume":"176","author":"Fayea","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"12","key":"10.1016\/j.bulcan.2024.10.013_bib0535","doi-asserted-by":"crossref","first-page":"e27904","DOI":"10.1002\/pbc.27904","article-title":"Changes in hepatitis B antibody status after chemotherapy in children with acute lymphoblastic leukemia","volume":"66","author":"Choi","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0540","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2141.2007.06601.x","article-title":"Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia","volume":"137","author":"Meisel","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0545","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2141.2009.07903.x","article-title":"Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia","volume":"147","author":"Lehrnbecher","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0550","doi-asserted-by":"crossref","first-page":"e28944","DOI":"10.1002\/pbc.28944","article-title":"Pneumococcal vaccination during chemotherapy in children treated for acute lymphoblastic leukemia","volume":"68","author":"Dorval","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"10.1016\/j.bulcan.2024.10.013_bib0555","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1002\/cncr.30764","article-title":"Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients","volume":"123","author":"Hung","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0560","unstructured":"Les infections invasives \u00e0 m\u00e9ningocoque en France en 2015, INVS, 2015 [Internet]. Disponible sur\u00a0: https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-a-prevention-vaccinale\/infections-invasives-a-meningocoque\/documents\/bulletin-national2\/les-infections-invasives-a-meningocoque-en-france-en-2015."},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0565","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1212\/WNL.0000000000002315","article-title":"Community-acquired bacterial meningitis in adults with cancer or a history of cancer","volume":"86","author":"Costerus","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.bulcan.2024.10.013_bib0570","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00006454-199910000-00013","article-title":"Meningitis in pediatric cancer patients: a review of forty cases from a single institution","volume":"18","author":"Sommers","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.bulcan.2024.10.013_bib0575","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/pbc.21174","article-title":"Immune response to conjugated meningococcal C vaccine in pediatric oncology patients","volume":"49","author":"Yu","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0580","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/ctr.13563","article-title":"Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Danziger-Isakov","year":"2019","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0585","doi-asserted-by":"crossref","first-page":"e20161890","DOI":"10.1542\/peds.2016-1890","article-title":"Recommendations for serogroup b meningococcal vaccine for persons 10\u00a0years and older","volume":"138","year":"2016","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.bulcan.2024.10.013_bib0590","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086\u00a0in healthy adolescents and young adults","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.bulcan.2024.10.013_bib0595","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614474","article-title":"A bivalent meningococcal b vaccine in adolescents and young adults","volume":"377","author":"Ostergaard","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0600","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017\u00a0European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0605","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10654-017-0334-z","article-title":"New cancer cases in France in 2015\u00a0attributable to infectious agents: a systematic review and meta-analysis","volume":"33","author":"Shield","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"26","key":"10.1016\/j.bulcan.2024.10.013_bib0610","first-page":"2568","article-title":"A 9-valent HPV vaccine in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0615","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"issue":"10108","key":"10.1016\/j.bulcan.2024.10.013_bib0620","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26\u00a0years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0625","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pvr.2017.03.002","article-title":"Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine\u00a0\u2013\u00a0a combined analysis of five phase III clinical trials","volume":"3","author":"Petersen","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2024.10.013_bib0630","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2024.42.16_suppl.10507","article-title":"Effects of HPV vaccination on the development of HPV-related cancers: a retrospective analysis of a United States-based cohort","volume":"42","author":"DeKloe","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.10.013_bib0635","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.33922","article-title":"Subsequent malignant neoplasms in the childhood cancer survivor study: occurrence of cancer types in which human papillomavirus is an established etiologic risk factor","volume":"128","author":"Henderson","year":"2022","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2024.10.013_bib0640","doi-asserted-by":"crossref","first-page":"1016.e1","DOI":"10.1016\/j.jtct.2021.08.020","article-title":"Increased incidence of human papillomavirus-related precancer or second malignancy among allogeneic stem cell transplantation patients: a SEER-medicare population study","volume":"27","author":"Zhao","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0645","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/bmt.2017.210","article-title":"Risks factors and timing of genital human papillomavirus (HPV) infection in female stem cell transplant survivors: a longitudinal study","volume":"53","author":"Shanis","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0650","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S2352-4642(21)00312-6","article-title":"Human papillomavirus vaccination for young survivors of cancer","volume":"6","author":"Brewer","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0655","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1186\/s12887-022-03562-1","volume":"22","author":"Landier","year":"2022","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0660","unstructured":"Sant\u00e9 Publique France. Rougeole Bulletin \u00e9pid\u00e9miologique Bilan 2022. Disponible sur\u00a0: file:\/\/\/Users\/aphaiaroussel\/Downloads\/bilan_rougeole_2022_VF.pdf."},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0665","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jama.1992.03480090085032","article-title":"Severe measles in immunocompromised patients","volume":"267","author":"Kaplan","year":"1992","journal-title":"JAMA"},{"issue":"30","key":"10.1016\/j.bulcan.2024.10.013_bib0670","doi-asserted-by":"crossref","first-page":"e4037","DOI":"10.1097\/MD.0000000000004037","article-title":"Increased risk of herpes zoster in children with cancer: a nationwide population-based cohort study","volume":"95","author":"Lin","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.bulcan.2024.10.013_bib0675","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21\u00a0specific cancers: population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.10.013_bib0680","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5045\/br.2016.51.4.249","article-title":"Clinical characteristics and outcomes of varicella zoster virus infection in children with hematologic malignancies in the acyclovir era","volume":"51","author":"Kim","year":"2016","journal-title":"Blood Res"},{"issue":"46","key":"10.1016\/j.bulcan.2024.10.013_bib0685","first-page":"3350","article-title":"Herpes zoster-associated morbidity in children undergoing chemotherapy for acute lymphoblastic leukaemia","volume":"171","author":"S\u00f8rensen","year":"2009","journal-title":"Ugeskr Laeger"},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0690","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0695","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijid.2003.09.006","article-title":"A review of the varicella vaccine in immunocompromised individuals","volume":"8","author":"Sartori","year":"2004","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.bulcan.2024.10.013_bib0700","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1097\/INF.0000000000001279","article-title":"Varicella vaccination of children with leukemia without interruption of maintenance therapy: a Danish experience","volume":"35","author":"Smedegaard","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0705","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.21203","article-title":"Epidemiology and outcomes of serious influenza-related infections in the cancer population","volume":"104","author":"Cooksley","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0710","unstructured":"Australian Governement, Department of Health and aged care. Vaccination for people who are immunocompromised [Internet]. Immunisation Handbook; Disponible sur\u00a0: https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccination-for-special-risk-groups\/vaccination-for-people-who-are-immunocompromised#people-with-cancer."},{"issue":"1","key":"10.1016\/j.bulcan.2024.10.013_bib0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/175.1.1","article-title":"Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients","volume":"175","author":"Potter","year":"1997","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2024.10.013_bib0720","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/adc.84.6.496","article-title":"Response to influenza immunisation during treatment for cancer","volume":"84","author":"Chisholm","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0725","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jpeds.2017.08.071","article-title":"The effectiveness of trivalent inactivated influenza vaccine in children with acute leukemia","volume":"191","author":"Sykes","year":"2017","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.bulcan.2024.10.013_bib0730","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/cam4.596","article-title":"Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer","volume":"5","author":"Kotecha","year":"2016","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.bulcan.2024.10.013_bib0735","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2352-4642(22)00315-7","article-title":"Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer","volume":"7","author":"Furlong","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"5","key":"10.1016\/j.bulcan.2024.10.013_bib0740","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1097\/MPH.0b013e3181d869f3","article-title":"The efficacy of influenza vaccination in a pediatric oncology population","volume":"32","author":"Reilly","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2024.10.013_bib0745","unstructured":"Vaccination dans le cadre de la Covid-19, Article HAS https:\/\/www.has-sante.fr\/jcms\/p_3178533\/fr\/vaccination-dans-le-cadre-de-la-covid-19."},{"issue":"9","key":"10.1016\/j.bulcan.2024.10.013_bib0375","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124004594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T16:07:48Z","timestamp":1737562068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124004594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0007455124004594"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.10.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination des enfants et adolescents trait\u00e9s pour une leuc\u00e9mie aigu\u00eb, hors allogreff\u00e9s\u00a0: recommandations du comit\u00e9 leuc\u00e9mies de la Soci\u00e9t\u00e9 fran\u00e7aise de lutte contre les cancers et les leuc\u00e9mies de l\u2019enfant et de l\u2019adolescent (SFCE)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}